Select a medication above to begin.
Symtuza
darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide
Black Box Warnings .
Hepatitis B Exacerbation
severe acute HBV exacerbations in HBV/HIV co-infected pts when D/C emtricitabine or tenofovir; monitor hepatic fxn closely for at least several months in HBV/HIV co-infected pts who D/C darunavir/cobicistat/emtricitabine/tenofovir alafenamide; initiate anti-HBV tx if needed
Adult Dosing .
Dosage forms: TAB: 800 mg/150 mg/200 mg/10 mg
HIV infection
- [1 tab PO qd]
- Info: for tx-naive pts or tx-experienced pts w/o darunavir or tenofovir resistance-assoc. substitutions; give w/ food
renal dosing
- [see below]
- CrCl <30: avoid use, dose adjustment not possible w/ fixed-dose combo
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: TAB: 800 mg/150 mg/200 mg/10 mg
HIV infection
- [>40 kg]
- Dose: 1 tab PO qd; Info: for tx-naive pts or tx-experienced pts w/o darunavir or tenofovir resistance-assoc. substitutions; give w/ food
renal dosing
- [see below]
- CrCl <30: avoid use, dose adjustment not possible w/ fixed-dose combo
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined